Menu

Recent Interviews

Matthew Salthouse, CEO, Kainantu Resources

Matthew Salthouse
CEO | Kainantu Resources
3 Phillip Street #19-01 Royal Group Building, 048693 Singapore (SGP)

info@krl.com.sg

+65 6920 2020

Interview Kainantu Resources: "We hold the key to growth in the Asia-Pacific region".


Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


John Jeffrey, CEO, Saturn Oil + Gas Inc.

John Jeffrey
CEO | Saturn Oil + Gas Inc.
Suite 1000 - 207 9 Ave SW, T2P 1K3 Calgary (CAN)

info@saturnoil.com

+1-587-392-7900

Saturn Oil + Gas CEO John Jeffrey: "Acquisition has increased production by 2,000%"


03. September 2021 | 13:27 CET

MorphoSys, Defence Therapeutics, CureVac, BioNTech - Dramatic need

  • Biotechnology
Photo credits: pixabay.com

While in Germany, 50.4 million citizens, or 60.7% of the population, are already fully vaccinated, and there is already discussion about booster vaccinations, the global average is just one in four. Thus, there is still an enormous demand for vaccines from various manufacturers. In addition to the French pharmaceutical Company Sanofi, a German vaccine producer could also celebrate a stock market comeback due to its second-generation vaccine.

time to read: 2 minutes by Stefan Feulner
ISIN: MORPHOSYS AG O.N. | DE0006632003 , DEFENCE THERAPEUTICS INC | CA24463V1013 , CUREVAC N.V. O.N. | NL0015436031


 

Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author


CureVac - On the road to approval

The disappointment at the final evaluation of the last clinical study was great at the Tübingen vaccine manufacturer CureVac. Vaccine protection of only 48% does not meet the statistical success criteria of at least 50% set by the WHO. Despite the sobering data, the Company wants to bring CVnCoV to approval. It is in "close contact with the European Medicines Agency (EMA) to seek regulatory approval to make the vaccine available to the large population for which it has been shown to be highly protective," CureVac informs. For investors, investing remains a gamble. From a technical perspective, the stock failed to continue its recovery and turned negative again. A drop below the EUR 55.40 mark would mean further pressure on the share. Thus, there is currently no reason to buy the stock.

Defence Therapeutics - Innovative technology

While BioNTech with EUR 67 billion and Moderna with no less than EUR 134 billion already have extreme valuations, the biotech Company Defence Therapeutics with just under EUR 183 million still has significant potential. The Canadian Company shines with a new method for fighting cancer and developing vaccines against infectious diseases.

The focus is on ACCUM technology, which enables the precise transport of vaccine antigens or antibody-drug conjugates in the intact form to the target cells. The aim is to achieve better efficiency and efficacy against serious diseases like cancer and infectious diseases such as COVID-19. Using the ACCUM method to deliver the ADCs into the cell accurately, cell penetration could be increased 10-fold compared to other approved ADC solutions.

A provisional US patent application was recently filed for acid-based hydrogels based on Accum technology, expanding the product portfolio. Hydrogels are linked polymer networks that can store a significant amount of water within their structure. They are used in various industries and have a broad range of applications in pharmaceuticals, therapeutics and hygiene products. According to a report by Expert Market Research, the global hydrogel market represents a dynamically growing sector with revenues of USD 23.6 billion in 2020, expected to reach USD 35.5 billion in 2026 with an expected compound annual growth rate of 7.0% over the next five years.

Defence Therapeutics already has a broad product portfolio around its promising Accum platform technology. In addition, the product pipeline remains well filled.

MorphoSys - Decisive brand

After the sell-off in recent weeks and a low of EUR 43.28, the biotech Company MorphoSys stabilized. Currently, the share price is struggling with the EUR 50 mark, which would complete the bottoming phase if it were to be broken through sustainably. Meanwhile, fewer positive assessments came from the United Kingdom. Here, the investment bank Barclays significantly lowered the price target of MorphoSys from EUR 90 to EUR 47. The rating was left at "equal weight".


The broad product range of Defence Therapeutics, based on Accum technology, offers high potential, but investment is also associated with risks at the current stage. An investment in the vaccine manufacturer CureVac is currently also a risk. In contrast, MorphoSys offers a good trading opportunity after exceeding the EUR 50 mark.


Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

15. September 2021 | 12:17 CET | by Nico Popp

Valneva, Cardiol Therapeutics, Sartorius: Healthy returns in every market phase

  • Biotechnology

The pandemic has given the healthcare sector a boost. If people were still somewhat hesitant to talk about the digitization of the healthcare system in 2019, the epidemic has clearly revealed where the weaknesses are. New drugs and procedures could also be tested under the new framework conditions. If nothing else, the industry is getting renewed attention as a result. We outline three companies and explain whether the shares have prospects or not.

Read

14. September 2021 | 13:10 CET | by Nico Popp

BioNTech, Defence Therapeutics, Valneva: Here, the overall market (almost) does not matter

  • Biotechnology

Is the crash coming or not? Meanwhile, even Wall Street banks are warning of an imminent crash event. Many commentators are jumping on the bandwagon. The reasons: Delta variation, supply problems and inflation, and an economy that could suffer. But if you compare the crashes of the past years, one thing becomes clear: Only the fewest price setbacks came with notice! We present three stocks that many investors believe can combine growth and security.

Read

10. September 2021 | 12:43 CET | by André Will-Laudien

NanoRepro, XPhyto Therapeutics, BioNTech, Valneva - The next biotech wave is rolling!

  • Biotechnology

So far, vaccine manufacturers can maintain their high valuation because the next wave of new infections is rolling in. In Germany, tests will be subject to fees starting in October, making public life more expensive for those who want to participate. In surveys, most German citizens have expressed support for fee-based testing; probably, the populations here should be separated into "vaccinated" and "unvaccinated" to indicate general opinion accurately. Four interesting values benefit from the current situation.

Read